News

2021-2022 Focus – Utility of DBM’s Diseased and Normal Human Cell Platforms and Bioassays in Metabolomics, Genomics, Proteomics and Medium-throughput Screening

DiscoveryBioMed, Inc. has matured into a premier Human Cell Models CRO by growing, expanding and leveraging its diseased and normal human cell cultures, platforms and bioassays into almost every human cell or tissue type. “There is no human cell that we will not culture or assay,” exclaimed Dr. Erik Schwiebert, DBM’s CEO and CSO. DBM is now executing larger projects with industry clients where we can perform targeted medium-throughput screening (MTS) using our human cell-driven bioassays, termed by us as “humanized drug discovery.” DBM also now believes that our diseased versus normal human cell cultures, particularly those grown in 3D Biogel culture formats as “organoids”, have important utility in metabolomics, genomics, and/or proteomics profiling of human disease. DBM will grow the human cells in the appropriate growth format and harvest the required samples for the client. DBM can perform metabolomic or genomic profiling itself “in house”, or it can provide the samples to the client and/or a third-party CRO for analysis. Please inquire via our CRO services inquiry portal on our website or via portals...

Read More

2021-2022 Focus – Validation of the Output of Artificial Intelligence-driven Drug Discovery Initiatives with DBM’s Diseased and Normal Human Cell Platforms and Bioassays

As a premier Human Cell Models CRO, a growing sector for DiscoveryBioMed, Inc. is validation of drug targets and drug candidates identified by artificial intelligence (AI)-based inquiry. AI can identify one or more drug targets for a particular human disease, and it can also identify existing small molecules to re-purpose and/or design new compounds that may engage the drug target. However, a key inflection or validation point is putting the AI-driven drug targets and candidates into practice. At present, DBM is helping multiple active AI clients validate drug targets and lead therapeutic assets in custom designed bioassays performed on primary human diseased and/or normal cell cultures. Validation at this key in vitro step is much less expensive than proceeding directly to an animal model of disease. If the targets and compounds are validated in DBM bioassays, refinement of the compounds can occur such as iterative medicinal chemistry and other approaches. Then, after deep profiling and optimization in vitro with DBM, one can proceed to develop the lead clinical candidates in the best animal model of...

Read More

2021-2022 Focus – Diseased and Normal Human Primary Cell Culture Creation

As a premier Human Cell Models CRO, a continuing focus for DiscoveryBioMed, Inc. is primary human cell culture creation. We have frequent inquiries about our capabilities across multiple tissue types. DBM has deep expertise in creating longer-lived primary cultures that also maintain physiological phenotypes. We have active efforts in multiple types of human sensory tissues as well as in human kidney, liver, and lung tissues. “Diseased versus normal human cell culture creation and their utility in 3D and 2D in vitro bioassays continues to be a huge emphasis for DBM,” explained Dr. Erik Schwiebert, CEO and CSO. “With uncertain outcomes in profiling lead therapeutic assets in rodent models of disease, our in vitro preclinical diseased versus normal human cell-driven bioassays have been adopted in parallel or in lieu of animal models.” A co-development agreement can also be discussed between the client and DBM to isolate and establish new human cell cultures, models and platforms. Please inquire via our CRO services inquiry portal on our website or via The Scientist, Science Exchange or LinkedIn if you...

Read More

Check out our most recent publication in Molecular Pharmacology!

In this article, we share how we can use our human taste bud tissue-derived cell (hTBEC) cultures to identify small molecules to suppress bitterness associated with a commonly used anti-HIV drug. This finding may be particularly helpful for pediatric and geriatric populations where compliance with an oral medicine because of bitter taste is a significant problem. This work was conducted by the combined efforts of DiscoveryBioMed’s new sensory cell sector Sentirix, the Monell Chemical Senses Center, a world leader in taste and smell research, and the Rutgers University Department of Nutritional Sciences. Read more in the link here! https://molpharm.aspetjournals.org/content/99/5/319

Read More

DiscoveryBioMed, Inc. Is Proving to Be an Advantageous CRO for Artificial Intelligence (AI) Firms Focused on Drug Target and Discovery for Human Genetic Diseases and Human Diseases in General

DiscoveryBioMed, Inc. is a niche CRO that specializes in the creation and use of diseased and normal human cell platforms in 'off the shelf' and customized in vitro bioassays.  Our services are particularly useful to recently established and emerging artificial intelligence firms focused on identifying new drug targets for human diseases and candidate small molecules that may be purposed and/or re-purposed for human diseases. Critically, the output of these AI processes needs to be tested in living, intact human cell platform technologies to (1) validate the AI-driven output and (2) optimize and refine the drug targets and candidate drugs in vitro in human cell platforms and assays of biological relevance and disease relevance before embarking on more expensive in vivo animal model studies and in vivo animal toxicology studies.  Please reach out to DBM on our website, www.discoverybiomed.com, and inquire via our CRO services inquiry portals located in many places on our webpages. We can follow up with a 'white paper' that summarizes our existing 'off the shelf' capacity and capabilities as well as introduce new human cell platforms and...

Read More

The Sage Group Is Representing DiscoveryBioMed, Inc. Actively in M&A Partnering

DiscoveryBioMed, Inc. (DBM) is excited to announce that The Sage Group is actively representing the company and our multiple assets in M&A partnering conversations. “We met Bill Mason, Wayne Pambianchi, and other principals for The Sage Group in BIO Digital, the 2020 virtual partnering event. They have deep experience in the life sciences and biotechnology sector and principals covering virtually every continent and market”, explained Dr. Erik Schwiebert, DBM’s Founder and Director. “DBM has completed 12 years of business and we are currently in our 13th year. Our CRO services business is growing and has a positive trajectory, we have multiple and different preclinical lead small molecule assets with a focus in the Human Renal Diseases landscape, and we have identified a unique niche in discovering, validating and/or profiling new small molecules or existing lead therapeutic assets in disease-relevant and biologically-relevant human cells from a plethora of different human tissues.” The Sage Group has Information Memoranda for both sides of the DBM business and they will be representing DBM at BIO Europe at the end...

Read More